Aligos Therapeutics (NASDAQ:ALGS) Upgraded by Jefferies Financial Group to “Strong-Buy” Rating

Aligos Therapeutics (NASDAQ:ALGS) was upgraded by equities research analysts at Jefferies Financial Group to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

A number of other research analysts also recently commented on ALGS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. UBS Group started coverage on shares of Aligos Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $20.00 target price for the company. Westpark Capital initiated coverage on shares of Aligos Therapeutics in a report on Thursday. They set a “buy” rating and a $48.00 price target on the stock. Wall Street Zen downgraded shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aligos Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Aligos Therapeutics Trading Up 1.1%

Shares of NASDAQ ALGS opened at $7.04 on Thursday. Aligos Therapeutics has a one year low of $3.76 and a one year high of $13.69. The firm has a market capitalization of $43.56 million, a PE ratio of -0.82 and a beta of 2.67. The business has a 50-day moving average price of $7.33 and a two-hundred day moving average price of $8.76.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%. Research analysts anticipate that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Trading of Aligos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ALGS. Rockefeller Capital Management L.P. grew its position in Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares in the last quarter. NorthCrest Asset Manangement LLC bought a new position in shares of Aligos Therapeutics during the 3rd quarter valued at $98,000. Susquehanna International Group LLP bought a new position in shares of Aligos Therapeutics during the 3rd quarter valued at $99,000. XTX Topco Ltd acquired a new stake in shares of Aligos Therapeutics in the 2nd quarter valued at $100,000. Finally, HRT Financial LP acquired a new stake in shares of Aligos Therapeutics in the 4th quarter valued at $106,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.